{
}
UBS has reiterated a Buy rating on AtriCure, maintaining a $60 price target despite the stock's recent decline to $34.52 following conservative guidance during the investor day. Analysts remain bullish, with price targets ranging from $45 to $66, as AtriCure aims for $750 million in sales by 2028 and a 14% EBITDA margin. The company's strong financial health and growth potential, highlighted by a 16.55% revenue increase over the past year, suggest that current market reactions may be an overreaction.
UBS has reiterated a Buy recommendation for AtriCure Inc., maintaining a price target of $60 despite a recent decline in shares following the company's conservative investor day presentation. AtriCure forecasts sales of $750 million by 2028, below consensus estimates, but analysts remain optimistic about the company's growth potential and financial health, with price targets ranging from $45 to $66. The company aims for $1 billion in revenue by 2030, focusing on product expansion and innovation to drive sustainable growth.
The convergence of science and technology is transforming healthcare, with Syfe's Healthcare Innovation portfolio offering diversified investment across genomics, biotechnology, pharmaceuticals, healthcare services, and medical devices. This portfolio includes six carefully selected ETFs, providing exposure to leading companies and innovations in the sector, while managing risks associated with long-term healthcare investments. With no minimum investment and low fees, it aims to capitalize on the future of healthcare advancements.
AtriCure, Inc. specializes in technologies for treating atrial fibrillation, managing the left atrial appendage, and postoperative pain relief. Their product range includes cardiac ablation tools like the Synergy Isolator forceps and CryoICE cryoablation system, as well as the AtriClip System for appendage management. These innovations support both open-heart and minimally invasive surgical procedures.
AtriCure, Inc. specializes in technologies for treating atrial fibrillation, managing left atrial appendage dilation, and post-operative pain. Their cardiac ablation and left atrial appendage management products are utilized in both open heart and minimally invasive surgeries, featuring devices like the Isolator Synergy clamps and the cryoICE cryoablation system. Additionally, their pain management solutions are employed during cardiothoracic procedures, enhancing surgical outcomes.
AtriCure, Inc. will participate in the UBS Global Healthcare Conference on November 12, 2024, at 5:00 pm PST, featuring a fireside chat with management. The company is known for its innovative surgical treatments for atrial fibrillation and related conditions, impacting over 37 million people globally. AtriCure's technologies include the FDA-approved Isolator® Synergy™ Ablation System and the widely used AtriClip® Left Atrial Appendage Exclusion System.
AtriCure, Inc.
Companies
| Symbol | ATRC |
| Name | AtriCure, Inc. |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Health Care Equipment & Services |
| Industry | Health Care Equipment & Supplies |
| Market | NASDAQ Global Select |
| Country | United States |
| State | OH |
| City | Mason |
| Zipcode | 45040 |
| Website | http://www.atricure.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs maintains buy rating on atricure with optimistic long term outlook
15:46 27.03.2025
ubs maintains buy rating for atricure with price target of sixty dollars
15:14 27.03.2025
healthcare innovation portfolio targets advancements in pharmaceuticals and medical technologies
Masimo Corporation
Vertex Pharmaceuticals Incorporated
Abbott Laboratories
GE HealthCare Technologies Inc.
AtriCure, Inc.
Regeneron Pharmaceuticals, Inc.
Intuitive Surgical, Inc.
CRISPR Therapeutics AG
Veeva Systems Inc.
Johnson & Johnson
Cigna
Integra LifeSciences Holdings Corporation
CVS Health Corporation
Stryker Corporation
UnitedHealth Group Incorporated
Amgen Inc.
Penumbra, Inc.
Alphatec Holdings, Inc.
UCB SA
Boston Scientific Corporation
Eli Lilly and Company
USA
BEL
Beigene
Revolution Medicines
Gilead Sciences
Exelixis
Incyte
Show more
02:52 13.11.2024
AtriCure Inc advances cardiac treatment technologies with strong market support
17:29 30.10.2024
AtriCure advances atrial fibrillation treatment with innovative ablation technologies
17:23 30.10.2024
AtriCure to Present at UBS Global Healthcare Conference in November 2024
13:00 28.10.2024
Trending
Subcategory
Corporate News
Stock Market Updates
Industry Trends
Finance Mergers & Acquisitions
Industry Mergers & Acquisitions
Global Financial Events
Market Analysis and Predictions
Banking Regulations
Financial Scams and Security
Retail and Consumer Goods
CEO Changes
Global Trade Developments
Central Bank Actions
Supply Chain Management
Startups & Entrepreneurship
Government Policies
Government Economic Policies
AI Innovations
Energy Sector Developments
Economic Sanctions
Countries:
Companies:
Barclays PLC
Tesla, Inc.
JPMorgan Chase & Co.
Bank of America Corporation
The Goldman Sachs Group, Inc.
NVIDIA Corporation
Wells Fargo & Company
Apple Inc.
UniCredit S.p.A.
UBS Group AG
Banco BPM S.p.A.
Amazon.com, Inc.
Citigroup Inc.
Google Inc.
Credit Suisse Real Estate Fund Siat
Deutsche Bank RV Global PP
Capital One Financial Corporation
BNP Paribas SA
Commerzbank AG
Lloyds Banking Group plc
Currencies:
United States Dollar
Euro
Indian Rupee
Swiss Franc
British Pound Sterling
Chinese Yuan
Japanese Yen
Hong Kong Dollar
Danish Krone
Australian Dollar
United Arab Emirates Dirham
Swedish Krona
Singapore Dollar
South Korean Won
Canadian Dollar
Russian Ruble
Malaysian Ringgit
Offshore Chinese Yuan
Kuwaiti Dinar
Ghanaian Cedi
People: